- Home
- NUVL vs NXST Comparison
NUVL vs NXST Comparison
Compare NUVL & NXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- NXST
- Stock Information
- Founded
- NUVL 2017
- NXST 1996
- Country
- NUVL United States
- NXST United States
- Employees
- NUVL N/A
- NXST N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- NXST Broadcasting
- Sector
- NUVL Health Care
- NXST Industrials
- Exchange
- NUVL Nasdaq
- NXST Nasdaq
- Market Cap
- NUVL 5.4B
- NXST 5.2B
- IPO Year
- NUVL 2021
- NXST 2003
- Fundamental
- Price
- NUVL $80.48
- NXST $181.27
- Analyst Decision
- NUVL Strong Buy
- NXST Strong Buy
- Analyst Count
- NUVL 10
- NXST 7
- Target Price
- NUVL $119.60
- NXST $206.43
- AVG Volume (30 Days)
- NUVL 582.7K
- NXST 286.5K
- Earning Date
- NUVL 08-07-2025
- NXST 08-07-2025
- Dividend Yield
- NUVL N/A
- NXST 4.10%
- EPS Growth
- NUVL N/A
- NXST 68.15
- EPS
- NUVL N/A
- NXST 19.70
- Revenue
- NUVL N/A
- NXST $5,357,000,000.00
- Revenue This Year
- NUVL N/A
- NXST N/A
- Revenue Next Year
- NUVL N/A
- NXST $10.32
- P/E Ratio
- NUVL N/A
- NXST $9.20
- Revenue Growth
- NUVL N/A
- NXST 8.00
- 52 Week Low
- NUVL $55.54
- NXST $141.66
- 52 Week High
- NUVL $113.51
- NXST $191.86
- Technical
- Relative Strength Index (RSI)
- NUVL 59.85
- NXST 64.49
- Support Level
- NUVL $76.27
- NXST $170.32
- Resistance Level
- NUVL $80.90
- NXST $175.22
- Average True Range (ATR)
- NUVL 2.55
- NXST 4.50
- MACD
- NUVL 0.19
- NXST 0.91
- Stochastic Oscillator
- NUVL 81.61
- NXST 85.37
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About NXST Nexstar Media Group Inc.
Nexstar is the largest television station owner-operator in the United States with over 200 stations in 116 markets, reaching 220 million people. Of its 200 stations, 155 are affiliated with the four national broadcast networks: CBS, Fox, NBC, and ABC. The 2019 merger with Tribune made Nexstar the top broadcast affiliate for both Fox and CBS as well as the number two partner for NBC and number three for ABC. The firm maintains stations in 13 of the top 20 television markets and reaches 68% of US TV households. Nexstar also owns NewsNation (formerly WGN), a cable news network, 75% of the fifth national broadcaster, the CW, and a 31% stake in Food Network and Cooking Channel.